Effect of Using Bitter Melon, Blueberries and Cranberries on HbA1c and Diabetes Symptom Levels

NCT ID: NCT07233460

Last Updated: 2025-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-06

Study Completion Date

2024-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This double-blind, randomized controlled trial investigated the effect of bitter melon, blueberry, and cranberry powder extract use on glycemic control and diabetes symptom levels in individuals with T2DM.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The increasing prevalence of Type 2 Diabetes Mellitus (T2DM) worldwide and the search for additional support to current treatments have increased interest in researching natural components such as bitter melon, blueberry, and cranberry, known for their antioxidant and hypoglycemic potential, as complementary therapies. This double-blind, randomized controlled trial investigated the effect of bitter melon, blueberry, and cranberry powder extract use on glycemic control and diabetes symptom levels in individuals with T2DM.

The study, conducted with four groups (bitter melon, blueberry, cranberry, and control), included 120 individuals diagnosed with T2DM. Individuals in the experimental group used 10g of powdered extract daily for 12 weeks, while those in the control group used nothing. The 'Patient Information Form' and 'Diabetes Symptoms Checklist Scale' were administered before the start of the study (pre-test/week 0) and at the end (post-test/week 12), and the venous blood value of the Hemoglobin A1c test (HbA1c) was measured.

In the experimental groups (bitter melon, blueberry, cranberry), after 12 weeks of treatment, statistically significant decreases were observed in HbA1c, the total score and all Subdimensions scores of the 'Diabetes Symptoms Checklist Scale', weight, and BMI compared to the control group; while in the control group, there was a significant increase in all parameters except HbA1c (p\<0.05). Although there was no difference between the experimental (bitter melon, blueberry, cranberry) groups in the intergroup measurements, HbA1c, the total mean scores of the Diabetes Symptom Checklist Scale, weight, and BMI were found to be significantly lower than in the control group (p\<0.05).

Bitter melon, blueberry, and cranberry powder extracts were found to be equally effective in reducing HbA1c, diabetes symptoms, weight, and BMI in T2DM patients. The lack of difference in efficacy between the three extracts in terms of glycemic and symptom levels suggests that these three natural products can be considered equivalent therapeutic options in the complementary treatment of T2DM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Symptoms and Signs Patient

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

As no reference could be made to any previous four-group study on the subject, and considering the small size of the city where the research would be conducted, it was decided to include a total of 120 individuals with T2DM in the study sample, with 30 individuals in each group (bitter melon group, blueberry group, cranberry group, and control group). However, considering reasons such as death, withdrawal from the study, or missing data, it was decided to increase the sample size by 10% to 132 individuals.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
The researcher who collected the data and the person who performed the statistics were blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bitter melon Group

Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.

Group Type EXPERIMENTAL

Bitter Melon Group

Intervention Type OTHER

Patients who voluntarily used bitter melon powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Blueberry Group

Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.

Group Type EXPERIMENTAL

Blueberry Group

Intervention Type OTHER

Patients who voluntarily used bitter blueberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Cranberry Group

Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.

Group Type EXPERIMENTAL

Cranberry Group

Intervention Type OTHER

Patients who voluntarily used cranberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Control Group

Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bitter Melon Group

Patients who voluntarily used bitter melon powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Intervention Type OTHER

Blueberry Group

Patients who voluntarily used bitter blueberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Intervention Type OTHER

Cranberry Group

Patients who voluntarily used cranberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being 18 years of age or older,
* Volunteering to participate in the study,
* Being conscious and able to communicate,
* Having been diagnosed with T2DM at least 3 months prior and currently using oral antidiabetic medication,
* Be using one of the following powder extracts-bitter melon, blueberry, or cranberry-for the first time as a complementary treatment upon a physician's recommendation and be on the first day of use,
* Not taking any other medications that affect blood sugar,
* No allergy to bitter melon, blueberry, or cranberry,
* Not engaging in exercise,
* Taking 10g of bitter melon, blueberry, or cranberry powder extract daily.

* Having previously received complementary therapy for DM, or having hearing loss.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karadeniz Technical University

OTHER

Sponsor Role collaborator

Hatice Demirağ, Ph.D

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hatice Demirağ, Ph.D

Assistant Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hatice Demirağ

Role: PRINCIPAL_INVESTIGATOR

Study Principal Investigator Gümüşhane Universıty

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gümüşhane University

Gümüşhane, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RCS05022024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Antidiabetic Potiential of Moringa and Dom Extract
NCT05898750 COMPLETED EARLY_PHASE1